주메뉴 바로가기 본문 바로가기
Pipeline
ADC와 합성신약 분야에 혁신적이고 독창적인 파이프라인을 보유하고 있습니다.

항생제
Program Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Marketed Partner Details
Delpazolid 그람양성균 -일반 결핵
-다제내성 결핵
-MRSA / VRE
-NTM

- Orphan Drug
- QIDP
- Fast Track

- L/O for China

항섬유화제
Program Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Marketed Partner Details
항응혈제
Program Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Marketed Partner Details
LCB02-0133 Nokxaban,FXa Inhibitor

L/O for global (Profit Sharing)

Sub L/O for China

Immuno Oncology
Program Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Marketed Partner Details
LCB39 LBG-STING agonist

- I/O Targeted
-Combi with ADC
-Payloads for ADC

LCB33 ENPP1 inhibitor

-Combi with ADCs